PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine

Circulation

Volumn 97, Issue 19, 1998, Pages 1960-1969

  Banai, Shmuel ^a  

^a BIKUR CHOLIM HOSPITAL   (Israel)

Author keywords

Muscle, smooth; Platelet derived factors; Restenosis; Tyrosine kinase; Tyrphostin

Indexed keywords

6,7 DIMETHYL 2 PHENYLQUINOXALINE; ENZYME INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POLYLACTIC ACID; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRALESIONAL DRUG ADMINISTRATION; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SWINE; VASCULAR SMOOTH MUSCLE;

EID: 0032546643     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.19.1960     Document Type: Article

References (43)

1. Indolfi C, Chiariello M, Avvedimento EV. Selective gene therapy for proliferative disorders: sense and antisense. Nat Med. 1996:2:634-635.
2. Levitzki A. Signal-transduction therapy, a novel approach to disease management. Ear J Biochem. 1994;226:1-13.
3. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 1995:267:1782-1788.
4. Shimokado K, Yokota T, Kosaka C, Zen K, Sasaguri T, Masuda J, Ogata J. Protein tyrosine kinase inhibitors inhibit both proliferation and chemotaxis of vascular smooth muscle cells. Ann NY Acad Sei. 1995;748: 171-175.
5. Yand ZH, Simari RD, Perkins ND, San H, Gordon D, Nabel GJ, Nabel EG. Role of the p21 cycling-dependent kinase inhibitor in limiting intimai cell proliferation in response to arterial injury. Proc Natl Acad Sei USA. 1996;93:7905-7910.
6. Egan SE, Weinberg RA. The pathway to signal achievement. Naiure. 1993:365:781-783.
7. Seedorf K. Intracellular signaling by growth factors. Metabolism. 1995; 44:24-32.
8. Shimokado K, Yokota T, Umezawa K, Sasaguri T, Ogata J. Protein tyrosine kinase inhibitors inhibit chemotaxis of vascular smooth muscle cells. Arterioscler Thromb. 1994;14:973-981.
9. Ito A, Shimokawa H, Kadokami T, Fukumoto Y, Owada MK, Shiraishi T, Nakaike R, Takayanagi T, Egashira K, Takeshita A. Tyrosine kinase inhibitor suppresses coronary arteriosclerotic changes and vasospastic responses induced by chronic treatment with interleukin-l in pigs in vivo. J Clin Invest. 1995:96:1288-1294.
10. Di Salvo J, Steusloff A, Semenchuk L, Satoh S, Kolquist K, Pfitzer G. Tyrosine kinase inhibitors suppress agonist-induced contraction in smooth muscle. Biomed Biochem Res Commun. 1993;3:968-974.
11. Bilder G, Krawiec JA, Gazit A, Gilon C, McVetry K, Lyall R, Zilberstein A, Levitzki A, Perrone M, Schreiber AB. Tyrphostins inhibit PDGF induced DNA synthesis, tyrosine specific protein kinase activity and c-fos mRNA expression in vascular smooth muscle cells. Am J Physiol. 1991; 260:C721-C730.
12. Bryckaert MC, Eldor A, Gazit A, Osherov N, Gilon C, Fontenay M, Levitzki A, Tobelem G. Inhibition of platelet derived growth factor (PDGF) induced mitogenic activity by PDGF receptor tyrosine kinase (tyrphostin) inhibitors. Exp Cell Res. 1992;199:255-261.
13. Levitzki A. Targeting signal transduction for disease therapy. Curr Opin CellBiol. 1996;8:239-244.
14. Mohammadi M, McMahon G, Lun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 1997;276: 955-960.
15. Kovalenko M, Ronnstrand L, Heldin C-H, Loubtchenkov M, Gazit A, Levitzki A, Bohmer FD. Phosphorylation site-specific inhibition of platelet-derived growth factor -receptor autophosphorylation by the receptor blocking tyrphostin AGI296. Biochemistry. I997;36:6260-6269.
16. 16. Golomb G, Fishbein I, Banai S, Mishaly D, Moscovite D, Gerte SD, Gazit A, Levitzki A. Controlled delivery of a tyrphostin inhibits intimai hyperplasia in a rat carotid artery injury model. Atherosclerosis. 1996;125: 171-182.
17. Grotendorst GR, Chang T, Seppa HEJ, Kleinman HK, Martin GR. Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells. J Cell Physiol. 1982;! 13:261-266.
18. Blank RS, Owens GK. Platelet-derived growth factor regulates actin isoform expression and growth state in cultured rat aortic smooth muscle cells. J Cell Physiol. 1990;142:635-642.
19. Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN, Schwarte SM. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol. 1990;! 11:2149-2155.
20. Jawien A, Bowen-Pope DF, Lindner V, Schwanz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimai thickening in a rat model of balloon angioplasty. J Clin Invest. 1992;89:507-511.
21. Nabel EG, Yang Z, Liptay S, San H, Gordon D, Haudenschild CC, Nabel GJ. Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimai hyperplasia in vivo. J Clin Invest. 1993; 91:1822-1829.
22. Raines EW, Ross R. Platelet-derived growth factor in vivo. In: Westermark B, Sorg C, eds. Cytokines. Basel, Switzerland: S. Karger AG; 1993;5:74-114.
23. Sirois MG, Simons M, Edelman ER. Antisense oligonucleotide inhibition of PDGFR- receptor subunit expression directs suppression of intimai thickening. Circulation. 1997;95:669-676.
24. Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin C-H, Waltenberger J, Bohmer FD, Levitzki A. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 1994;54:6106-6114.
25. Gazit A, App H, McMahon G, Chen J, Levitzki A, Bohmer FD. Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. J Med Client. 1996:39:2170-2177.
26. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation. 1996;94:1647-1654.
27. Ross R. Smooth muscle cell, II: growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol. 1971;50:172-186.
28. Clemmons DR, Van Wyk JJ. Evidence for a functional role of endogenously produced somatomedinlike peptides in the regulation of DNA synthesis in cultured human fibroblasts and porcine smooth muscle cells. J Clin Invest. 1985;75:1914-1918.
29. Sumpio BE, Banes AJ. Response of porcine aortic smooth muscle cells to cyclic tensional deformation in culture. J Surg Res. 1988;44:696-701.
30. Yamada KM, Kennedy DW, Hayashi M. Fibronectin in cell adhesion, differentiation, and growth. In: Sato GH, Pardee AB, Sirbasku DA, eds. Growth of Cells in Hormonally Defined Media. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1982:131-143.
31. Weinstein R, Hoover GA, Stemerman MB, van der Spek J, Maciag T. Fibronectin dependence for attachment in vitro: smooth muscle cell versus fibroblast. In: Sato GH, Pardee AB, Sirbasku DA, eds. Growth of
32. Cells in Hormonally Defined Media. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1982:145-154.
33. Jaffe EA. Culture of human endothelial cells. Transplant Proc. 1980;12: 49-53.
34. Klein-Soyer C, Stierte A, Bouderbala B, Cazenave JP. Effect of an extract of human brain containing growth factor activity on the proliferation of human vascular endothelial cells in primary culture. Biol Cell. 1984; 52:9-20.
35. Burger AM, Kaur G, Alley MC, Supko JO, Malspeis L, Grever MR, Sausville EA. Tyrphostin AG17, [(3,5-di-tert-butyl-4hydroxybenzylidene)-malononitrile], inhibits cell growth by disrupting mitochondria. Cancer Res. 1995:55:2794-2799.
36. Banai S, Schneider A, Gertz SD, Colomb G, Levitzki A, Wolf Y. Effect of non-selective protein tyrosine kinase blocker on porcine aortic, human arterial, and atheroma-derived SMCs proliferation. J Am Coll Cardiol. 1996;27:410A. Abstract.
37. 36. Banai S, Schneider A, Gertz SD, Golomb G, Levitzki A, Wolf Y. Effect of selective PDGF-receptor versus non-selective protein tyrosine kinase blockers on aortic SMCs and endothelial cell proliferation. J Am Coll Cardiol. 1996;27:255A. Abstract.
38. 37. Movat H. Demonstration of all connective tissue elements in a single section. Arch Palhol Lab Med. 1955;60:289-295.
39. Kenagy RD, Vergel S, Mattsson E, Bendeck M, Reidy MA, Clowes AW. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler Thromb Vase Biol. 1996;16:1373-1382.
40. Bornfeld KE. Intracellular signaling in arterial smooth muscle migration versus proliferation. Trends Cardiomsc Med. 1996;6:143-151.
41. Asahara T, Bauters C, Pastore CJ, Kearney M, Rossow S, Bunting S, Ferrara N, Symes JF, Isner JM. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimai hyperplasia in balloon-injured rat carotid artery. Circulation. 1995; 91:2793-2801.
42. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96:2260-2268.
43. Hart CE, Clowes AW. Platelet-derived growth factor and arterial response to injury. Circulation. 1997;95:555-556.